Shock, Cardiogenic
Recent clinical, regulatory, research and industry developments relating to this disease.
Myocardial localization of coronavirus in COVID-19 cardiogenic shock.
Intraaortic balloon support for myocardial infarction with cardiogenic shock.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
- Q4 2026Multi-center, Randomized, Placebo-controlled, Double-blind Phase 1b/2a Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Invobenitug Also Knows as Procizumab (PCZ; AK1967) in Patients With Cardiogenic Shock and Elevated Circulating Dipeptidyl Peptidase 3 (cDPP3) Concentrations
Clinical MilestonesViewHide
- 2026-07-09Multi-center, Randomized, Placebo-controlled, Double-blind Phase 1b/2a Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Invobenitug Also Knows as Procizumab (PCZ; AK1967) in Patients With Cardiogenic Shock and Elevated Circulating Dipeptidyl Peptidase 3 (cDPP3) ConcentrationsResults expected Q4 2026
- 2026-05-01CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic ShockResults expected Q4 2026
- 2026-07-09ClinicalMulti-center, Randomized, Placebo-controlled, Double-blind Phase 1b/2a Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Invobenitug Also Knows as Procizumab (PCZ; AK1967) in Patients With Cardiogenic Shock and Elevated Circulating Dipeptidyl Peptidase 3 (cDPP3) ConcentrationsResults expected Q4 2026
- 2026-05-01ClinicalCAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic ShockResults expected Q4 2026
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Shock, Cardiogenic3
- Hospital Mortality2
- American Heart Association1
- Cardiology1
- Heart Failure1
- Hemodynamics1
- Internationality1
- Intra-Aortic Balloon Pumping1
Leading journals6
- Circulation3
- European journal of heart failure2
- The New England journal of medicine2
- Circulation. Heart failure1
- JAMA1
- Journal of cardiac failure1
Leading researchers8
- Thiele H4
- Katz JN3
- Morrow DA3
- Baird-Zars VM2
- Berg DD2
- Bohula EA2
- Chaudhry SP2
- Desch S2
Affiliations (unnormalised)6
- Brigham and Women's Hospital3
- Mayo Clinic2
- St Vincent Heart Center2
- University of Alberta2
- University of California2
- University of Utah2
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Cardiogenic shock is a high-acuity state of end-organ hypoperfusion caused by a marked reduction in cardiac output in the setting of heart disease. It is a complex and hemodynamically diverse syndrome that can progress to multisystem organ failure and death.
It develops after an acute cardiac insult or underlying heart disease that diminishes cardiac output. The supplied grounding does not specify particular etiologies beyond this general cardiac origin.
The core mechanism is inadequate cardiac pumping leading to reduced systemic perfusion and end-organ hypoperfusion. The syndrome is described as multifactorial and progressive, with an initial cardiac insult followed by organ failure and, in severe cases, death.
Underlying heart disease and an acute cardiac insult increase risk. The literature also indicates that a patient's broader cardiac condition and overall medical condition influence whether cardiogenic shock develops and how severe it becomes.
Management includes best medical therapy, surgical approaches, mechanical circulatory support, and palliative care. Contemporary guidance also emphasizes timely, appropriately selected therapy, phenotyping of patients, and organized regional systems of care, but the supplied grounding does not support a more specific treatment hierarchy.
AI-generated summary grounded in MeSH and 2 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Shock resulting from diminution of cardiac output in heart disease.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.